Australia has become the first country outside of the United States to approve the use of the drug pegcetacoplan (SYFOVRE) to slow down the progression of geographic atrophy.

Opthea Limited (NASDAQ:OPT), a biopharmaceutical company with a market capitalization of $894.5 million specializing in the ...

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age‐related macular degeneration (wet AMD) and diabetic ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

The goal is to educate the public and professionals about AMD and support patients and families affected by vision impairment ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Long-term stabilizing of retinal exudation and fluid accumulation contributes to brolucizumab’s efficacy in managing wet age-related macular degeneration (AMD). Visual prognosis could be improved when ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.